The EU Civil Society Forum on HIV sent the following statement to the European Commission ahead of the Board of the Global Fund to fight AIDS, Tuberculosis and Malaria next week which will decide on how much money countries around the world will receive to ...

European CHMP adopts positive opinion for Gilead’s Vemlidy® (tenofovir alafenamide, TAF) for the treatment of chronic hepatitis B virus infection Vemlidy demonstrated similar efficacy with improvements in renal and bone laboratory safety parameters compared to Viread in Phase 3 studies FOSTER CITY, Calif.–Nov. 11, 2016– Gilead Sciences, ...

Scientists have developed a type of HIV test on a USB stick. The device, created by scientists at Imperial College London and DNA Electronics, uses a drop of blood to detect HIV, and then creates an electrical signal that can be read by a computer, laptop ...

On October 27 – 28th, a group of 35 advocates from around the world attended a meeting, Financing HIV and TB Services and Advocacy in Middle Income Countries: Developing an Action Plan sponsored by ICSS and Open Society Foundations to develop an Action Plan to ...

Several oral presentations at Glasgow 2016 provided data on simplification strategies. In the first study, Roberta Gagliardini from the Institute of Clinical Infectious Diseases in Rome presented results from the multi-site open-label Italian ATLAS-M study that randomised 266 participants on stable ART with ritonavir-boosted atazanavir (ATZ/r) ...

A recent study found that sofosbuvir-based therapy is safe to treat patients with hepatitis C virus (HCV) who also have mental health disease (MHD), and that there may even be benefits, although it is unclear how long the benefits may last. The study was published ...

The Liver Meeting is organized by the American Association for the Study of Liver Diseases and is being held in Boston, US on November 11-15. New combination therapy could cure hepatitis C with only 4 weeks of treatment Is there an increased risk of cancer ...

Cabotegravir levels still measurable a year after last injection in one in six participants A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of subjects who were given an experimental injectable drug as HIV pre-exposure prophylaxis ...

The combination of ledipasvir and sofosbuvir was effective and well-tolerated among patients with acute hepatitis C genotype 1, according to researchers in Germany. Researchers wrote that short-duration HCV treatments could prevent the spread of the virus, and could be less expensive compared with the cost of ...

Theratechnologies announces results from the last pivotal Phase III trial of HIV long acting biologic (LAB) investigational antiretroviral ibalizumab Ibalizumab maintains significant reduction of viral load in patients with multi-drug resistant HIV-1 over 24 weeks Results from the study support the regulatory submission of the BLA to ...

Eight weeks of treatment with AbbVie’s investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) achieved high SVR rates across all major genotypes of chronic hepatitis C 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 ...

The European Medicines Agency developed a brochure on the European regulatory system for medicines. The booklet explains how the European regulatory system for medicines operates. It describes how medicines are authorized and monitored in the European Union (EU) and how the European medicines regulatory network – ...

Open Society Foundations have examined sex worker-led programs that protect health and rights and have published a detailed and thoughtful report. The report describes programs in 5 countries: Kenya, Zimbabwe, Ukraine, Kyrgyzstan, South Africa. SWAN members from Ukraine and Kyrgyzstan, All-Ukrainian Charitable Organization «LEGALIFE-UKRAINE» and ...

Romanian civil society organizations signed a Joint Statement appealing to the participants of the 36th meeting of the Global Fund Board.

Young women aged 15–24 years are at particularly high risk of HIV infection, accounting for 20% of new HIV infections among adults globally in 2015, despite accounting for just 11% of the adult population. In sub-Saharan Africa, young women accounted for 25% of new HIV ...

A combination of interventions for HIV that reflect alternative routes to program strengthening and encourage country programs to evaluate costs, impact and clinical benefits of immediate initiation should be prioritized over individual high-cost interventions such as the universal test-and-treat strategy in regions with limited resources, ...

Health ministers from eastern Europe and central Asia adopted on 3 November in Minsk, Belarus, a consensus statement on HIV and tuberculosis (TB) treatment for all, calling for expanded and rapidly scaled-up access to affordable, quality-assured medicines. Representatives of Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, the ...

The Government of Ukraine has announced that in 2017 it will fully finance from its budget the national opioid substitution therapy programme for people who use drugs, a key population in Ukraine that is at higher risk of HIV infection. Approximately US$ 500 000 will ...